Logistic regression model to examine H–Y antibodies and transplantation outcomes
. | ≥1 H–Y antibody detected . | . | . | . | |
|---|---|---|---|---|---|
| Clinical outcomes . | Yes n = 39 (%) . | No n = 36 (%) . | Unadjusted odds ratio (95% CI) . | Adjusted odds ratio*(95% CI) . | |
| Acute GVHD II-IV | 10 (26) | 15 (42) | 0.48 (0.18-1.28) | 0.24 (0.05-1.23) | |
| Acute GVHD 0-I | 29 (74) | 21 (58) | P = .15 | P = .11 | |
| Chronic GVHD | 34 (87) | 11 (31) | 15.5 (4.8-50.1) | 56.5 (7.5-425) | |
| No cGVHD | 5 (13) | 25 (69) | P < .0001 | P < .0001 | |
| Relapse | 0 | 13 (36) | 0.02 (0.001-0.39) | — | |
| No relapse | 39 (100) | 23 (64) | P < .0001 | ||
| cGVHD and no relapse | 34 (87) | 11 (31) | 7.4 (2.1-25.8)† | 22.2 (2.4-206)† | |
| No cGVHD and no relapse | 5 (13) | 12 (33) | P = .001‡ | P = .006‡ | |
| Relapse and no cGVHD | 0 (0) | 13 (36) | 0.08 (0.004-1.7)† | — | |
. | ≥1 H–Y antibody detected . | . | . | . | |
|---|---|---|---|---|---|
| Clinical outcomes . | Yes n = 39 (%) . | No n = 36 (%) . | Unadjusted odds ratio (95% CI) . | Adjusted odds ratio*(95% CI) . | |
| Acute GVHD II-IV | 10 (26) | 15 (42) | 0.48 (0.18-1.28) | 0.24 (0.05-1.23) | |
| Acute GVHD 0-I | 29 (74) | 21 (58) | P = .15 | P = .11 | |
| Chronic GVHD | 34 (87) | 11 (31) | 15.5 (4.8-50.1) | 56.5 (7.5-425) | |
| No cGVHD | 5 (13) | 25 (69) | P < .0001 | P < .0001 | |
| Relapse | 0 | 13 (36) | 0.02 (0.001-0.39) | — | |
| No relapse | 39 (100) | 23 (64) | P < .0001 | ||
| cGVHD and no relapse | 34 (87) | 11 (31) | 7.4 (2.1-25.8)† | 22.2 (2.4-206)† | |
| No cGVHD and no relapse | 5 (13) | 12 (33) | P = .001‡ | P = .006‡ | |
| Relapse and no cGVHD | 0 (0) | 13 (36) | 0.08 (0.004-1.7)† | — | |
— indicates odds ratio is not determinable.
Logistic regression model variables included patient age, donor age, related versus unrelated donors, bone marrow versus peripheral blood stem cell source, myeloablative versus nonablative conditioning regimens, T-cell depletion, disease at conditioning, good prognosis at conditioning, and acute GVHD
“No cGVHD and no relapse” is the referent group
cGVHD and no relapse versus no cGVHD and no relapse